Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke

Abstract

When edaravone dexborneol versus edaravone was administered within 48 hours after AIS, 90-day good functional outcomes favored the edaravone dexborneol group, especially in female patients. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02430350.